| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | -288.98% | -1091.69% | -623.82% | 44.60% | 54.48% | 66.92% | -35.45% |
| EBITDA Margin | -264.43% | -1048.21% | -559.66% | 50.34% | 58.33% | 69.00% | -21.64% |
| Net Margin | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% | 51.00% | -19.04% |
| Current Ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | — |
| Quick Ratio | 11.23 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | — |
| Debt / Equity | — | — | — | — | — | — | — |
| ROE | -15.14% | -15.42% | -12.70% | 12.85% | 14.96% | 14.32% | — |
| ROA | -10.79% | -11.97% | -9.84% | 10.29% | 11.64% | 11.83% | — |
| Asset Turnover | 0.06 | 0.02 | 0.03 | 0.32 | 0.28 | 0.23 | — |
| Book Value / Share | 3.24 | 3.59 | 3.98 | 3.92 | 3.22 | 3.16 | — |
AbCellera Biologics Inc. is a biotechnology company based in Vancouver, Canada, focused on discovering and developing therapeutic antibodies. The company operates a technology-driven antibody discovery platform that integrates biology, computation, and engineering to identify drug candidates from natural immune responses for a wide range of diseases. AbCellera’s platform searches, decodes, and analyzes immune systems at scale, aiming to generate high-quality antibody leads that can be advanced into clinical development by AbCellera or its partners. It collaborates with pharmaceutical and biotechnology companies to create antibody-based medicines across multiple indications and modalities, including complex and hard-to-drug targets. Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera Biologics Inc. plays a specialized role in the biopharmaceutical ecosystem as an innovation partner, providing discovery capabilities that support the development of new antibody therapeutics for global healthcare markets.